Cassava Sciences Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 0/6
Die Erträge von Cassava Sciences sind jährlich um durchschnittlich -55% zurückgegangen, während in der Branche Pharmaceuticals die Erträge jährlich um rückgegangen sind und sich dabei auf 0.4% belaufen.
Wichtige Informationen
-55.0%
Wachstumsrate der Gewinne
-46.3%
EPS-Wachstumsrate
Pharmaceuticals Wachstum der Industrie | 6.0% |
Wachstumsrate der Einnahmen | n/a |
Eigenkapitalrendite | -60.9% |
Netto-Marge | n/a |
Letzte Ertragsaktualisierung | 31 Mar 2024 |
Jüngste Aktualisierungen vergangener Leistungen
Keine Aktualisierungen
Recent updates
Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans
Oct 17We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely
Jul 04We're Not Very Worried About Cassava Sciences' (NASDAQ:SAVA) Cash Burn Rate
Mar 05Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans
Nov 19Cassava Sciences begins extension study of Alzheimer's drug simufilam
Oct 13Cassava Sciences Stock: Huge Returns Or Catastrophic Losses
Sep 29Cassava Sciences: Trying To Manage Expectations
Sep 21Cassava Sciences reaches over five-month high on rising volumes
Sep 09Cassava Sciences Looks As Good Of A Purchase As Ever
Sep 03Cassava Sciences stock jumps 10% after director buys $860K shares
Aug 26Cassava Sciences rally continues as stock up 39%
Aug 17Cassava's Simufilam And Acetylcholinesterase Inhibitors: Similar Results
Aug 11Cassava Sciences GAAP EPS of -$0.48 misses by $0.06
Aug 03We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely
Aug 03Cassava Sciences sheds 44% on report of criminal probe linked to Alzheimer’s drug
Jul 27Cassava Sciences And Alzheimer's Disease: A Precipitious Path
Jun 10Cassava Sciences: 3 Upcoming Catalysts That Could Decide Bull / Bear Debate
May 31Cassava Sciences (NASDAQ:SAVA) has More Than Enough Funding to Function Until the Approval Process is Finished, but Investors may Need to be Ready for a Long Wait
Apr 193 Key Points To Remember About Cassava Sciences
Apr 07Retractions Of A Key Collaborator's Papers Set Up A Big April For Cassava Sciences
Mar 31Cassava Sciences: Why The Stock Is Rangebound
Feb 28The FDA Deals Another Blow To Cassava Sciences' Bears
Feb 11Cassava Sciences, Inc.: Recent Trading Activity Presents An Opportunity
Feb 02INmune Bio, The Biotech In My Stable For After Cassava Sciences
Jan 17Cassava Sciences, Inc. - The Short Squeeze Has Started
Jan 06Cassava Sciences, Inc. - A Rational Expectation If All Goes Well With Simufilam
Dec 30Companies Like Cassava Sciences (NASDAQ:SAVA) Are In A Position To Invest In Growth
Dec 28Cassava Sciences Stock: Here We Go Again
Dec 21Cassava Sciences Teaches Us 4 Lessons To Find The Next Big Thing
Dec 02Cassava Sciences Gets Underway Putting Simufilam To The Test
Nov 24Cassava Sciences: Data Rules!
Nov 17Cassava Sciences' Hypothesis Raises Doubts
Nov 08Cassava Sciences Stock: Massive Potential Marred By Controversy
Nov 01Cassava Sciences: Welcome To The Casino
Oct 25Has Cassava Sciences Put Out The Fire For Now?
Sep 28Cassava Sciences: Medical History In The Making
Sep 21Cassava Sciences: One Doubtful Drug For One Doubtful Indication
Sep 15We Think Cassava Sciences (NASDAQ:SAVA) Can Afford To Drive Business Growth
Sep 14More On Cassava Sciences' Controversy
Sep 04Cassava Sciences Likely To Survive Latest Attack On Alzheimer's Drug, But Caveat Emptor
Aug 26Aufschlüsselung der Einnahmen und Ausgaben
Wie Cassava Sciences Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
---|---|---|---|---|
31 Mar 24 | 0 | -48 | 16 | 0 |
31 Dec 23 | 0 | -97 | 17 | 0 |
30 Sep 23 | 0 | -95 | 16 | 0 |
30 Jun 23 | 0 | -90 | 14 | 0 |
31 Mar 23 | 0 | -83 | 13 | 0 |
31 Dec 22 | 0 | -76 | 12 | 0 |
30 Sep 22 | 0 | -71 | 13 | 0 |
30 Jun 22 | 0 | -61 | 12 | 0 |
31 Mar 22 | 0 | -46 | 10 | 0 |
31 Dec 21 | 0 | -32 | 8 | 0 |
30 Sep 21 | 0 | -21 | 5 | 0 |
30 Jun 21 | 0 | -13 | 4 | 0 |
31 Mar 21 | 0 | -9 | 4 | 0 |
31 Dec 20 | 0 | -6 | 4 | 0 |
30 Sep 20 | 0 | -5 | 3 | 0 |
30 Jun 20 | 0 | -4 | 3 | 0 |
31 Mar 20 | 0 | -4 | 3 | 0 |
31 Dec 19 | 0 | -5 | 3 | 0 |
30 Sep 19 | 0 | -4 | 3 | 0 |
30 Jun 19 | 0 | -4 | 3 | 0 |
31 Mar 19 | 0 | -6 | 3 | 0 |
31 Dec 18 | 0 | -7 | 4 | 0 |
30 Sep 18 | 0 | -8 | 4 | 0 |
30 Jun 18 | 0 | -10 | 4 | 0 |
31 Mar 18 | 0 | -11 | 4 | 0 |
31 Dec 17 | 0 | -12 | 4 | 0 |
30 Sep 17 | 0 | -12 | 5 | 0 |
30 Jun 17 | 0 | -13 | 5 | 0 |
31 Mar 17 | 0 | -12 | 5 | 0 |
31 Dec 16 | 0 | -15 | 6 | 0 |
30 Sep 16 | 0 | -17 | 5 | 0 |
30 Jun 16 | 0 | -17 | 6 | 0 |
31 Mar 16 | 0 | -17 | 6 | 0 |
31 Dec 15 | 0 | -14 | 5 | 0 |
30 Sep 15 | 0 | -12 | 5 | 0 |
30 Jun 15 | 0 | -12 | 5 | 0 |
31 Mar 15 | 0 | -12 | 5 | 0 |
31 Dec 14 | 0 | -12 | 5 | 0 |
30 Sep 14 | 35 | 23 | 5 | 0 |
30 Jun 14 | 37 | 26 | 5 | 0 |
31 Mar 14 | 39 | 29 | 5 | 0 |
31 Dec 13 | 41 | 32 | 5 | 0 |
30 Sep 13 | 8 | -3 | 6 | 0 |
30 Jun 13 | 9 | -4 | 7 | 0 |
Qualität der Erträge: SAVA ist derzeit unrentabel.
Wachsende Gewinnspanne: SAVA ist derzeit unrentabel.
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: SAVA ist unrentabel, und die Verluste haben in den letzten 5 Jahren mit einer Rate von 55% pro Jahr zugenommen.
Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von SAVA verglichen werden, da das Unternehmen derzeit nicht profitabel ist.
Erträge im Vergleich zur Industrie: SAVA ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Pharmaceuticals (19.9%) erschwert.
Eigenkapitalrendite
Hohe Eigenkapitalrendite: SAVA hat eine negative Eigenkapitalrendite (-60.95%), da es derzeit unrentabel ist.